CandlesenseCandlesense
BIIB•benzinga•

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

Summary

FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with home-based weekly autoinjector dosing.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 14, 2025 by benzinga

← Back to BIIB News
    FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi | BIIB Stock News | Candlesense